The point-of-care glucose testing market size has grown steadily in recent years. It will grow from $4.91 billion in 2024 to $5.15 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to growing prevalence of diabetes, increased awareness of diabetes management, expansion of the aging population, rise in healthcare infrastructure, adoption of point-of-care testing.
The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to expansion of telemedicine services, growing emphasis on personalized medicine in diabetes care, rise in diabetes management programs, increased investment in glucose testing research and development, adoption of continuous glucose monitoring. Major trends in the forecast period include development of wearable glucose monitoring devices, integration of smartphone connectivity in glucose testing, growth of point-of-care testing in home healthcare settings, adoption of artificial intelligence in glucose data analysis, expansion of remote patient monitoring for diabetes.
The increasing prevalence of diabetes is expected to drive the growth of the point-of-care glucose testing market in the coming years. Diabetes is a chronic metabolic condition that raises blood glucose levels, leading to long-term complications, including severe damage to the heart, blood vessels, eyes, kidneys, and nerves. Point-of-care glucose testing is widely used to monitor glucose levels in hospitalized patients, enabling quick treatment decisions in response to changes in glycemia and improving diabetes management and therapeutic outcomes. For example, in June 2024, according to NHS England, the number of individuals identified with pre-diabetes in England rose to 3,615,330 in 2023, an 18% increase from 3,065,825 in 2022. Moreover, cases among individuals under 40 surged by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising prevalence of diabetes is fueling the growth of the point-of-care glucose testing market.
The growth of the point-of-care glucose testing market is further fueled by the rising aging population. As demographics shift toward an aging population, characterized by an increasing proportion of elderly individuals, point-of-care glucose testing becomes increasingly crucial. This technology serves essential purposes for older individuals, particularly those at higher risk of diabetes or already diagnosed. The World Health Organization projected that by 2030, one out of every six individuals globally would be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion, and by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Therefore, the growing aging population is a significant driver of the point-of-care glucose testing market.
Product innovation is a key trend gaining traction in the point-of-care glucose testing market, with major companies focused on developing innovative products. For instance, F. Hoffmann-La Roche AG introduced Cobas Pulse in January 2022, a new point-of-care blood glucose monitor designed for healthcare staff. This handheld device includes an automated glucose test strip reader, camera, and touchscreen, housed in a rugged casing that can be disinfected and used across all age groups, including newborns and intensive care patients. The innovation aims to enhance physicians' workflow by integrating Glucommander dosage software and offering downloadable decision-support apps.
Major companies in the point-of-care glucose testing market are also directing their efforts towards developing advanced solutions such as glucose-ketone monitoring sensors. Abbott Laboratories announced in June 2022 the development of a first-of-its-kind biowearable sensor system that continuously monitors glucose and ketones in diabetic patients. This breakthrough device, granted FDA designation, represents a significant advancement in regulatory status and is set to become the most compact and slender monitoring device globally. It integrates seamlessly with Abbott's digital ecosystem, allowing remote monitoring by healthcare professionals.
In August 2024, F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, acquired Point of Care technology from LumiraDx Ltd. for an undisclosed sum. This acquisition enables Roche to enhance its diagnostics portfolio by incorporating a versatile platform that consolidates multiple tests into a single instrument, thereby supporting the growth of decentralized healthcare solutions. LumiraDx Ltd. is a UK-based company specializing in point-of-care diagnostics, particularly glucose testing solutions.
Major companies operating in the point-of-care glucose testing market include F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, TaiDoc Technology Corporation, B. Braun Melsungen AG, Beckman Coulter Inc., Nipro Corporation, Dexcom Inc., Bio-Rad Laboratories Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings plc, Trinity Biotech plc, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc.
North America was the largest region in the point of care glucose testing market in 2024. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Point-of-care glucose testing denotes a quality-assured pathology service administered in close proximity to the patient rather than within the conventional confines of a clinical laboratory. Clinicians or individuals employ small handheld units or glucose analyzers, along with testing strips, for glucose testing on whole blood. This approach reduces the duration from specimen collection to result verification, leading to swifter therapeutic intervention, diminished preanalytical errors, and enhanced patient care.
The primary components in point-of-care glucose testing encompass lancet and lancing devices, strips, and meters. Lancets, small sharp instruments, puncture the skin to extract a small blood drop for testing, while lancing devices securely hold the lancet and are activated with a simple button push. These devices facilitate straightforward blood withdrawal and assessment of blood glucose levels using a blood glucose monitor and test strips in point-of-care glucose testing. Testing sites include fingertips and alternate site testing, applied in both type-1 and type-2 diabetes. Various end-users, such as professional diagnostic centers, hospitals and clinics, home care settings, among others, utilize these methods.
The point-of-care glucose testing market research report is one of a series of new reports that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to expansion of telemedicine services, growing emphasis on personalized medicine in diabetes care, rise in diabetes management programs, increased investment in glucose testing research and development, adoption of continuous glucose monitoring. Major trends in the forecast period include development of wearable glucose monitoring devices, integration of smartphone connectivity in glucose testing, growth of point-of-care testing in home healthcare settings, adoption of artificial intelligence in glucose data analysis, expansion of remote patient monitoring for diabetes.
The increasing prevalence of diabetes is expected to drive the growth of the point-of-care glucose testing market in the coming years. Diabetes is a chronic metabolic condition that raises blood glucose levels, leading to long-term complications, including severe damage to the heart, blood vessels, eyes, kidneys, and nerves. Point-of-care glucose testing is widely used to monitor glucose levels in hospitalized patients, enabling quick treatment decisions in response to changes in glycemia and improving diabetes management and therapeutic outcomes. For example, in June 2024, according to NHS England, the number of individuals identified with pre-diabetes in England rose to 3,615,330 in 2023, an 18% increase from 3,065,825 in 2022. Moreover, cases among individuals under 40 surged by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the rising prevalence of diabetes is fueling the growth of the point-of-care glucose testing market.
The growth of the point-of-care glucose testing market is further fueled by the rising aging population. As demographics shift toward an aging population, characterized by an increasing proportion of elderly individuals, point-of-care glucose testing becomes increasingly crucial. This technology serves essential purposes for older individuals, particularly those at higher risk of diabetes or already diagnosed. The World Health Organization projected that by 2030, one out of every six individuals globally would be 60 years old or older. The proportion of the population aged 60 and over is expected to rise from 1 billion in 2020 to 1.4 billion, and by 2050, the global population of individuals aged 60 and older is anticipated to double, reaching 2.1 billion. Therefore, the growing aging population is a significant driver of the point-of-care glucose testing market.
Product innovation is a key trend gaining traction in the point-of-care glucose testing market, with major companies focused on developing innovative products. For instance, F. Hoffmann-La Roche AG introduced Cobas Pulse in January 2022, a new point-of-care blood glucose monitor designed for healthcare staff. This handheld device includes an automated glucose test strip reader, camera, and touchscreen, housed in a rugged casing that can be disinfected and used across all age groups, including newborns and intensive care patients. The innovation aims to enhance physicians' workflow by integrating Glucommander dosage software and offering downloadable decision-support apps.
Major companies in the point-of-care glucose testing market are also directing their efforts towards developing advanced solutions such as glucose-ketone monitoring sensors. Abbott Laboratories announced in June 2022 the development of a first-of-its-kind biowearable sensor system that continuously monitors glucose and ketones in diabetic patients. This breakthrough device, granted FDA designation, represents a significant advancement in regulatory status and is set to become the most compact and slender monitoring device globally. It integrates seamlessly with Abbott's digital ecosystem, allowing remote monitoring by healthcare professionals.
In August 2024, F. Hoffmann-La Roche AG, a healthcare company based in Switzerland, acquired Point of Care technology from LumiraDx Ltd. for an undisclosed sum. This acquisition enables Roche to enhance its diagnostics portfolio by incorporating a versatile platform that consolidates multiple tests into a single instrument, thereby supporting the growth of decentralized healthcare solutions. LumiraDx Ltd. is a UK-based company specializing in point-of-care diagnostics, particularly glucose testing solutions.
Major companies operating in the point-of-care glucose testing market include F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, TaiDoc Technology Corporation, B. Braun Melsungen AG, Beckman Coulter Inc., Nipro Corporation, Dexcom Inc., Bio-Rad Laboratories Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings plc, Trinity Biotech plc, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc.
North America was the largest region in the point of care glucose testing market in 2024. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Point-of-care glucose testing denotes a quality-assured pathology service administered in close proximity to the patient rather than within the conventional confines of a clinical laboratory. Clinicians or individuals employ small handheld units or glucose analyzers, along with testing strips, for glucose testing on whole blood. This approach reduces the duration from specimen collection to result verification, leading to swifter therapeutic intervention, diminished preanalytical errors, and enhanced patient care.
The primary components in point-of-care glucose testing encompass lancet and lancing devices, strips, and meters. Lancets, small sharp instruments, puncture the skin to extract a small blood drop for testing, while lancing devices securely hold the lancet and are activated with a simple button push. These devices facilitate straightforward blood withdrawal and assessment of blood glucose levels using a blood glucose monitor and test strips in point-of-care glucose testing. Testing sites include fingertips and alternate site testing, applied in both type-1 and type-2 diabetes. Various end-users, such as professional diagnostic centers, hospitals and clinics, home care settings, among others, utilize these methods.
The point-of-care glucose testing market research report is one of a series of new reports that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Point-of-Care Glucose Testing Market Characteristics3. Point-of-Care Glucose Testing Market Trends and Strategies4. Point-of-Care Glucose Testing Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Point-of-Care Glucose Testing Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Point-of-Care Glucose Testing Market34. Recent Developments in the Point-of-Care Glucose Testing Market
5. Global Point-of-Care Glucose Testing Growth Analysis and Strategic Analysis Framework
6. Point-of-Care Glucose Testing Market Segmentation
7. Point-of-Care Glucose Testing Market Regional and Country Analysis
8. Asia-Pacific Point-of-Care Glucose Testing Market
9. China Point-of-Care Glucose Testing Market
10. India Point-of-Care Glucose Testing Market
11. Japan Point-of-Care Glucose Testing Market
12. Australia Point-of-Care Glucose Testing Market
13. Indonesia Point-of-Care Glucose Testing Market
14. South Korea Point-of-Care Glucose Testing Market
15. Western Europe Point-of-Care Glucose Testing Market
16. UK Point-of-Care Glucose Testing Market
17. Germany Point-of-Care Glucose Testing Market
18. France Point-of-Care Glucose Testing Market
19. Italy Point-of-Care Glucose Testing Market
20. Spain Point-of-Care Glucose Testing Market
21. Eastern Europe Point-of-Care Glucose Testing Market
22. Russia Point-of-Care Glucose Testing Market
23. North America Point-of-Care Glucose Testing Market
24. USA Point-of-Care Glucose Testing Market
25. Canada Point-of-Care Glucose Testing Market
26. South America Point-of-Care Glucose Testing Market
27. Brazil Point-of-Care Glucose Testing Market
28. Middle East Point-of-Care Glucose Testing Market
29. Africa Point-of-Care Glucose Testing Market
30. Point-of-Care Glucose Testing Market Competitive Landscape and Company Profiles
31. Point-of-Care Glucose Testing Market Other Major and Innovative Companies
35. Point-of-Care Glucose Testing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Point-of-Care Glucose Testing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on point-of-care glucose testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point-of-care glucose testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The point-of-care glucose testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Lancet and Lancing Devices; Strips; Meters2) By Testing Site: Fingertips; Alternate Site Testing
3) By Applications: Type-1 Diabetes; Type-2 Diabetes
4) By End-User: Professional Diagnostic Centers; Hospitals and Clinics; Home Care Settings; Other End Users
Subsegments:
1) By Lancet and Lancing Devices: Single-Use Lancets; Multi-Use Lancets; Adjustable Lancing Devices2) By Strips: Glucose Test Strips; Ketone Test Strips; Combo Strips (Glucose and Ketone)
3) By Meters: Blood Glucose Meters; Continuous Glucose Monitoring (CGM) Meters; Bluetooth-Enabled Meters
Key Companies Mentioned: F Hoffmann-La Roche Ltd.; Abbott Laboratories Inc.; Danaher Corporation; Siemens Healthineers; Becton, Dickinson and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- F Hoffmann-La Roche Ltd.
- Abbott Laboratories Inc.
- Danaher Corporation
- Siemens Healthineers
- Becton, Dickinson and Company
- TaiDoc Technology Corporation
- B. Braun Melsungen AG
- Beckman Coulter Inc.
- Nipro Corporation
- Dexcom Inc.
- Bio-Rad Laboratories Inc.
- LifeScan Inc.
- Nova Biomedical Corporation
- Ypsomed AG
- Ascensia Diabetes Care Holdings AG
- Trividia Health Inc.
- Radiometer Medical ApS
- HemoCue AB
- EKF Diagnostics Holdings plc
- Trinity Biotech plc
- Bionime Corporation
- PTS Diagnostics
- ForaCare Inc.
- Menarini Diagnostics
- ACON Laboratories Inc.
- Senseonics Holdings Inc.
- Prodigy Diabetes Care LLC
- Nemaura Medical Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 5.15 Billion |
| Forecasted Market Value ( USD | $ 6.51 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
